c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma

British Journal of Ophthalmology

Volumn 83, Issue 1, 1999, Pages 110-114

  Ghana, J S ^a   Wilson, G D ^b   Cree, I A ^c   Alexander, R A ^c   Myatt, N ^c   Neale, M ^c   Foss, A J E ^d   Hungerford, J L ^e  

^a RAFT Institute of Plastic Surgery   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; ONCOGENE C MYC; PRIORITY JOURNAL; SCHOOL CHILD; UVEA MELANOMA;

EID: 0033008658     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.83.1.110     Document Type: Article

References (39)

1. Albert DM, Niffenegger AS, Wilson JK. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 1992;36:429-38.
2. Prescher G, Bornfeld N, Hirsche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347:1222-5.
3. Sisley K, Cottam DW, Rennie IG, et al. Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma. Genes Chromosom Cancer 1992;5:197-200.
4. Horsthemke B, Prescher G, Bornfeld N, et al. Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. Genes Chromosom Cancer 1992;4:217-21.
5. Gordon KB, Thompson CT, Char DH, et al. Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma. Cancer Res 1994;54:4764-8.
6. Speicher MR, Prescher G, du Manoir S, et al. Chromosomal gains and losses in uveal melanoma detected by comparative genomic hybridization. Cancer Res 1994;54:3817-23.
7. Kishore K, Ghazvini S, Char DH, et al. p53 gene and cell cycling in uveal melanoma. Am J Ophthalmol 1996;121:561-7.
8. Tobal K, Warren W, Cooper CA, et al. Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer 1992;66:900-4.
9. Jay V, Yi Q, Hunter WS, Zielenska M. p53 expression in uveal malignant melanomas. Pathology 1996;28:306-8.
10. Merbs SL, Green WR, Jen J, et al. Microsatellite analysis of 9p21 in primary uveal melanoma. Invest Ophthahnol Vis Sci 1997;38:S463.
11. Singh AD, Wang MX, Donoso LA, et al. Genetic aspects of uveal melanoma: a brief review. Semin Oncol 1996;23:768-72.
12. Riou GF. Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. Cancer Surv 1988;7:442-55.
13. Field JK, Spandidos DA, Stell PM, et al. Elevated expression of c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989;4:1463-8.
14. Grover R, Ross DA, Sanders R, et al. C-myc oncoprotein, an independent prognostic marker for intermediate thickness primary melanoma. Plast Recomtr Surg 1998;(in press).
15. Grever R, Ross DA, Wilson GD, et al. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma. Plast Reconstr Surg 1997;50:478-82.
16. Royds JA, Sharrard RM, Parsons MA, et al. C-MYC oncogene expression in ocular melanomas. Graefes Arch Clin Exp Ophtlmtmol 1992;230:366-71.
17. Singh AD, Donoso LA. Genetic aspects of uveal melanoma. Int Ophthalmol Clin 33:47-52.
18. Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosom Cancer 1997;19:22-8.
19. Mooy CM, Luyten GP, de Jong PT, et al. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 1995;147:1097-104.
20. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in nbroblasts by c-myc protein. Cell 1992;69:119-28.
21. Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-6.
22. Jay V, Yi Q, Hunter WS, et al. Expression of Bcl-2 in uveal malignant melanoma. Arch Pathol Lab Med 1996;120:497-8.
23. Coupland SE, Bechrakis NE, Bornfeld N, et al. Cyclin DI (BCL-1) protein expression in choroidal melanoma. Invest Ophthahnol Vis Sci 1997;38:S464.
24. Foss AJE, Alexander RA, Jefferies LW, et al. Microvessel count predicts survival in uveal melanoma. Cancer Res 1996;56:2900-3.
25. Watson JV, Sikora KE, Evan GI. A simultaneous flow cytometric assay for c-myc oncoprotein and DNA in nuclei from paraffin-embedded material. J Immunol Meth 1985;83:179-92.
26. Watson JV, Stewart J, Evan GI, et al. The clinical signficance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer 1986;53:331-7.
27. Foss AJE, Alexander RA, Hungerford JL, et al. Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol 1997;81:2900-3.
28. Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Gen Dev 1993;3:44-9.
29. Ramsay JA, From L, Kahn HJ. bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995;8:150-1.
30. Tron VA, Krajewski S, Klein-Parker H, et al. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 1995;146:643-50.
31. Grover R, Wilson GD. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur J Surg Oncol 1996;22:347-9.
32. Imesch PD, Albert DM. Apoptosis in uveal and skin melanomas. Invest Ophthalmol Vis Sci 1997;38:S803.
33. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-52.
34. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-57.
35. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the MD Anderson Cancer Center experience and prognostic factors. Cancer 1995;76:1665-70.
36. Lassam NJ, From L, Kahn HJ, Over expression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993;53:2235-8.
37. Cristofoiini M, Boi S, Girlando S, et al. p53 protein expression in nevi and melanoma. Arch Dermatol 1993;129:739-43.
38. Petty RD, Cree IA, Sutherland LA, et al. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Biophys Biochem Res Comm 1994;199:264-70.
39. Myatt N, Cree IA, Kurbacher CM, et al. The ex vivo chemosensitivity profile of choroidal melanoma. Anti-Cancer Drugs 1997;8:756-62.